and Association with Paclitaxel Pharmacokinetics. Clin Pharmacol Ther 81, 76-82

Size: px
Start display at page:

Download "and Association with Paclitaxel Pharmacokinetics. Clin Pharmacol Ther 81, 76-82"

Transcription

1 Original Papers Rezvani K, Yong AS,Tawab A, Jafarpour B, Enaife R, Mielke S, Savani BN, Keywanfar K, Li Y, Kurlander R, Barett AJ (2009). Ex vivo charecterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia an acute an chronic myeloid leukemia. Blood 113, Mielke S, Nunes R, Rezvani K, Fellowes VS, Venne A, Solomon SR, Fan Y, Gostick E, Price DA, Scotto C, Read EJ, Barrett AJ (2008): A clinical scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique. Blood 111, Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J, Jafarpour B, Boss C, Barrett AJ (2008): Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 111, Mielke S*, Rezvani K*, Savani BN, Nunes R, yong ASM, Schindler J, Kurlander R, Ghetie V, Read EJ, Solomon SR, Vitetta ES, Barrett AJ (2007):Reconstitution of foxp3+ regulatory T cells (T regs ) after CD25-depleted allotransplantion in elderly patients and association with acute graft-versus-host disease (GvHD). Blood 100, [*authors contributed equally] Savani BN, Mielke S, Adams S, Uribe M, Rezvani K, Yong ASM, Zeilah J, Kurlander R, Srinivasan R, Childs R, Hensel N, Barrett AJ (2007): Natural killer cell recovery strongly influences major transplant outcomes following T cell depleted HLA identical stem cell transplantation. Leukemia 21, Savani BN, Mielke S, Rezvani K, Montero A, Yong ASM, Wisch L, Superata J, Kurlander R, Singh A, Childs R, Barrett AJ (2007): Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T-cell depleted allogeneic stem cell transplantation, Biol Blood Marrow Transpl 13, Solomou EE, Rezvani K*, Mielke S*, Malide D*, Keyvanfar K, Visconte V, Kajigaya S, Barrett AJ, Young NS (2007): Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia [Brief report], Blood 110, [*authors contributed equally] Rezvani K, Yong ASM, Savani BN, Mielke S, Keyvanfar K, Gostick E, Price D, Douek D, Barrett AJ (2007): Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes following allogeneic stem cell transplantation for acute lymphoblastic leukemia (ALL). Blood 110, Smith NF, Marsh S, Scott-Horton TJ, Hamada A, Mielke S, Mross K, Figg WD, Verweij J, McLeod HL, Sparreboom A (2007): Variants in the SLCO1B3 gene: Interethnic Distribution

2 and Association with Paclitaxel Pharmacokinetics. Clin Pharmacol Ther 81, Yong ASM, Rezvani K, Savani BN, Eniafe R, Mielke S, Goldman JM, Barrett AJ (2007): High PR3 or ELA2 expression by CD34+ cells in advanced phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide driven graft-versus-leukemia effects. Blood 110, Rezvani K*, Mielke S*, Ahmadzadeh M, Kilical Y, Savani BN, Zeilah J, Keyvanfar K, Montero A, Hensel N, Kurlander R, Barrett AJ (2006): Reconstitution of Foxp3-positive regulatory T-cells (TREGS) following HLA-matched T-depleted allogeneic stem cell transplantation (SCT): relationship of donor and patient TREGS with GVHD, Blood 108, [*authors contributed equally] Savani BN, Rezvani K, Mielke S, Montero A, Kurlander R, Childs R, Leitman SF, CS Carter, EJ Read, Barrett AJ (2006): Factors associated with early molecular remission following T cell depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 107, Savani BN, Montero A, Srinivasan R, Singh A, Shenoy A, Mielke S, Rezvani K, Karimpour S, Childs R, Barrett AJ (2006): Chronic GVHD and pre-transplant abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long term survivors after stem cell transplantation. Biol Blood Marrow Transplant 12, Montero A, Savani BN, Shenoy A, Read EJ, Carter CS, Leitman SF, Mielke S, Rezvani K, Childs R, Barrett AJ (2006): T-cell depleted peripheral blood stem cell allotransplantation for patients with hematological malignancies: Effect of chronic GVHD on outcome. Biol Blood Marrow Transplant 12, Sissung TM, Mross K, Steinberg SM, Behringer D, Figg WD, Sparreboom A, Mielke S (2006): Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer 42, Mielke S, Sparreboom A, Steinberg S, Gelderblom H, Unger C, Behringer D, Mross K (2005): Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res 11, Mielke S, Sparreboom A, Behringer D, Mross K (2005): Paclitaxel pharmacokinetics and response to chemotherapy in patients with advanced cancer treated with a weekly regimen. Anticancer Res 25, Solomon SR, Mielke S, Savani BN, Montero A, Wisch L, Childs R, Hensel N, Schindler J, Ghetie V, Leitman S, Mai T, Carter CS, Kurlander R, Read EJ, Vitetta ES, Barrett JA (2005): Selective depletion of alloreactive donor lymphocytes a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 105,

3 Henningsson A, Marsh S, Loos WJ, Karlsson MO, Garsa A, Mross K, Mielke S, Viganò L, Locatelli A, Verweij J, Sparreboom A, McLeod HL (2005): Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 Polymorphisms with the Pharmacokinetics of Paclitaxel. Clin Cancer Res 11, Rezvani K, Brenchley JM, Price DA, Kilical Y, Gostick E, Sewell AK, Li J, Mielke S, Douek DC, AJ Barrett (2005): T-cell responses directed against multiple HLA A*0201-restricted epitopes derived from WT1 in patients with leukemia and healthy donors: identification, quantification and characterization, Clin Cancer Res, 11, Jackisch C, Grothey A, Schlotter CM, Mielke S, Waßmann KI, Behringer D, Mross K, Rody A (2004): Practical aspects in the treatment of metastatic breast cancer with administration of paclitaxel weekly. [Praktische Aspekte der Therapie des metastasierten Mammakarzinoms mit Paclitaxel-weekly.] Geburtsh Frauenheilk 64, Mielke S, Mross K, Gerds TA, Schmidt A, Wäsch R, Berger DP, Lange W, Behringer D (2003): Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h. Anticancer Drugs 14, Mross K, Häring B, Holländer N, Mielke S, Behringer D, Unger C (2002): Comparison of the 1-hour and 3-hours paclitaxel infusion pharmacokinetics: Results from a randomized trail. Onkologie 25, Gelderblom H, Mross K, Tije AJ, Behringer D, Mielke S, Zomeren DM, Verweij J, Sparreboom A (2002): Comparative pharmacokinetics of unboundpaclitaxel during 1- and 3- hour infusions. J Clin Oncol 20, Jakob M, Mielke S, Keller H, Metzger U (1999): Results of therapy after primary conservative management of distal radius fractures in patients over 65 years of age. [Therapieergebnisse nach primär konservativer Versorgung distaler Radiusfrakturen bei Patienten im Alter von über 65 Jahren.] Handchir Mikrochir Plast Chir 31, Mielke S, Meden H, Kuhn W (1998): Expression of the c-erbb-2 encoded oncoprotein p185 HER-2/neu in pregnancy as a model for oncogene-induced carcinogenesis. Med Hypotheses 50, Mielke S, Meden H, Marx D, Wuttke W, Kuhn W (1997): In vivo effects of estrogens on c- erbb-2 oncoprotein levels in chorionic villous tissue and maternal serum. Gynecol Endocrinol 11, Mielke S, Meden H, Raab T, Wuttke W, Kuhn W (1997): Effects of interfering and influencing factors on the analyses of p105 (c-erbb-2, HER-2) oncoprotein fragment in serum. Anticancer Res 17,

4 Meden H, Mielke S, Schauer A, Kuhn W (1997): Serum levels of the c-erbb-2 HER2/neu encoded oncoprotein fragment p105 in normal pregnancies. In Vivo 11, Meden H, Mielke S, Wuttke W, Kuhn W (1997): Elevated serum levels of the c-erbb-2 encoded oncoprotein fragment in cases of pure preeclampsia and HELLP syndrome. J Obstet Gynaecol Res 23, Meden H, Mielke S, Marx D, Wuttke W, Kuhn W (1997): Hormonal treatment with sex steroids in women is associated with lower p105 serum concentrations. Anticancer Res 17, Meden H, Mielke S, Wuttke W, Kuhn W (1995): Increased serum level of c-erbb-2-coded protein p105 in patients with pre-eclampsia.[erhöhte Serumspiegel des c-erbb-2-codierten Proteins p105 bei Patientinnen mit Präeklampsie.] Gynäkol Geburtshilfliche Rundsch 35 (Suppl 1), Case Reports Schoen C, Unzicker C, Stuhler G, Elias J, Einsele H, Grigoleit GU, Abele-Horn M, Mielke S (2009). Life-threatening infection caused by daptomycin-resistant Corynebacterium jeikeium in a neutropenic patient. J Clin Microbiol, 2009 May 6. [Epub ahead of print] Mielke S, Potthoff K, Feuerhake F, Bley TA, Windfuhr M, Bertz H, Finke J (2007): Fatal leukoencephalopathy after reduced-intensity allogeneic stem cell transplantation. Onkologie 30, Lohr J, Mielke S, Lübbert M, Behringer D (2003): Fatal outcome in a patient with metastatic prostate cancer and acquired severe hypogammaglobulinemia with complete absence of mature peripheral blood B-cells. In Vivo 17, Reviews Mielke S (2007): Individualized pharmacotherapy with paclitaxel. Curr Opin Oncol 19, Mielke S, Sparreboom A, Mross K (2006): Peripheral neuropathy, a persisting challenge in paclitaxel-based regimes. Eur J Cancer 42, Mielke S, Solomon SR, Barrett AJ (2005): Selective depletion strategies in allogeneic stem cell transplantation. Cytotherapy 7, Book Chapters and Contributions Mielke S (2009): Peripheral neuropathy. in: Encyclopaedia of Cancer. 2 nd edition 2008; hrsg. von Schwab M; Springer Verlag, Berlin, invited, in press

5 Mielke S, Barrett AJ (2009): Management of relapse and minimal residual disease after stem cell allotransplantation. in: Hematopoietic Stem Cell Transplantation in Clinical Practice. 1 st edition 2009; edited by Treleaven J & Barrett AJ; Elsevier Verlag, Edingburgh, Chapter 40: Finke J, Potthoff K, Mielke S, Bertz H (2002): Allogenic stem cell transplantation from related and unrelated donors for active leukemia or lymphoma: feasibility and results in elderly patients. in: High-Dose Therapy and Transplantation of Haematopoietic Stem Cells Proceedings of the 5 th International Stem Cell Workshop, Bad Saarow/Berlin, Germany, April 26 th -28 th, st English- language edition 2002; hrsg. von Schultze W; Blackwell Verlag, Berlin, Wien, Meden H, Marx D, Raab T, Mielke S, Kron M, Wuttke W, Schauer A, Kuhn W (1994): Erhöhte Serumspiegel des Onkoproteins p185 (c-erbb-2) bei Patientinnen mit Ovarialkarzinom: Erste Ergebnisse mit einem neuen ELISA. Zitiert nach dem Buchbeitrag des Vortrags (gehalten von Meden am 7. Oktober 1994) in: 10. Arbeitsgespräch der Tumorimmunologie in der Gynäkologie, Ulm, 7. bis 8. Oktober 1994, Aktuelle Aspekte der Tumorimmunologie in der Gynäkologie; hrsg. v. Kreienberg R., Grill HJ, Möbus V, Koldovsky U, Zuckschwerdt Verlag, München, Aktuel Onkol 86, 33-36

Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation: Questions and Answers. Key Points

Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation: Questions and Answers. Key Points CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Bone Marrow Transplantation

More information

Hematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine

Hematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cell Transplantation Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cells Harvested from blood, bone marrow, umbilical cord blood Positive selection of CD34 (+) cells

More information

Blood-Forming Stem Cell Transplants

Blood-Forming Stem Cell Transplants Blood-Forming Stem Cell Transplants What are bone marrow and hematopoietic stem cells? Bone marrow is the soft, sponge-like material found inside bones. It contains immature cells known as hematopoietic

More information

Cord Blood Stem Cell Transplantation

Cord Blood Stem Cell Transplantation LEUKEMIA LYMPHOMA MYELOMA FACTS Cord Blood Stem Cell Transplantation No. 2 in a series providing the latest information on blood cancers Highlights Umbilical cord blood, like bone marrow and peripheral

More information

Stem Cell Transplantation

Stem Cell Transplantation Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance

More information

information for payers and referrers

information for payers and referrers a d u lt s t e m c e l l t r a n s p l a n tat i o n p r o g r a m information for payers and referrers Spring 2014 For more information, visit www.dfbwcc.org/bmt. o u r expertise Since its founding in

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll

More information

Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Breast Cancer

Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Breast Cancer Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Breast Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem_cell_transplantation_for_breast_cancer

More information

Pros and Cons of Stem Cell Sources and their availability in Africa. Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa

Pros and Cons of Stem Cell Sources and their availability in Africa. Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa Pros and Cons of Stem Cell Sources and their availability in Africa Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa Introduction The ability to perform a haematopoietic stem

More information

MEDICAL COVERAGE POLICY

MEDICAL COVERAGE POLICY Important note Even though this policy may indicate that a particular service or supply is considered covered, this conclusion is not necessarily based upon the terms of your particular benefit plan. Each

More information

Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Breast Cancer

Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Breast Cancer Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Breast Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem_cell_transplantation_for_breast_cancer

More information

GRANIX (tbo-filgrastim)

GRANIX (tbo-filgrastim) RATIONALE FOR INCLUSION IN PA PROGRAM Background Neutropenia is a hematological disorder characterized by an abnormally low number of neutrophils. A person with severe neutropenia has an absolute neutrophil

More information

Selecting an appropriately matched donor for hematopoietic

Selecting an appropriately matched donor for hematopoietic Transplant Outcomes in Acute Leukemia (I) Mary Eapen a and John E. Wagner b Umbilical cord blood (UCB) has gradually emerged over the last decade as an alternative source of hematopoietic cells for transplantation

More information

What is a Stem Cell Transplantation?

What is a Stem Cell Transplantation? What is a Stem Cell Transplantation? Guest Expert: Stuart, MD Associate Professor, Medical Oncology www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Drs. Ed and Ken. I am

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_epithelial_ovarian_cancer 2/2001 11/2015 11/2016 11/2015 Description

More information

UMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE

UMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE UMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE HIND AL HUMAIDAN, MD,FRCPA Director, Blood Bank (Donor & Transfusion Services) and Stem Cell Cord Blood Bank Consultant Hematopathologist INTRODUCTION

More information

Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each

Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each Introduction 1.1 Introduction: About 10,500 new cases of acute myelogenous leukemia are diagnosed each year in the United States (Hope et al., 2003). Acute myelogenous leukemia has several names, including

More information

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle TITLE PROJET NOM HOPITAL Assessment of tumor angiogenesis using PET/CT with 18 F-Galacto- RGD. (PNC_29_001) Division of

More information

Challenges of Hematopoietic Stem Cell Transplantation. Robert J. Soiffer, MD Dana Farber Cancer Institute

Challenges of Hematopoietic Stem Cell Transplantation. Robert J. Soiffer, MD Dana Farber Cancer Institute Challenges of Hematopoietic Stem Cell Transplantation Robert J. Soiffer, MD Dana Farber Cancer Institute Hematopoietic Stem Cell Transplantation Objectives Deliver sufficient chemo-radio therapy to destroy

More information

Infosheet. Allogeneic stem cell transplantation in myeloma. What is the principle behind stem cell transplantation?

Infosheet. Allogeneic stem cell transplantation in myeloma. What is the principle behind stem cell transplantation? Infosheet Allogeneic stem cell transplantation in myeloma High-dose therapy and autologous stem cell transplantation is currently the first-line treatment standard of care for younger/fitter myeloma patients.

More information

ACUTE MYELOID LEUKEMIA (AML),

ACUTE MYELOID LEUKEMIA (AML), 1 ACUTE MYELOID LEUKEMIA (AML), ALSO KNOWN AS ACUTE MYELOGENOUS LEUKEMIA WHAT IS CANCER? The body is made up of hundreds of millions of living cells. Normal body cells grow, divide, and die in an orderly

More information

Stem Cell Transplantation in Severe Aplastic Anemia

Stem Cell Transplantation in Severe Aplastic Anemia Stem Cell Transplantation in Severe Aplastic Anemia Dr. D. Goodyear MD, FRCPC Division of Hematology and Hematological Malignancies, University of Calgary 1 of 11 Introduction Most cases of aplastic anemia

More information

Bone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? Federica Giannotti, MD Eurocord-Hôpital Saint Louis, Paris

Bone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? Federica Giannotti, MD Eurocord-Hôpital Saint Louis, Paris Bone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? Federica Giannotti, MD Eurocord-Hôpital Saint Louis, Paris Background Hematopoietic stem cell transplantation (HSCT) is

More information

Fetal Maternal Immunity and Antileukemia Activity in Cord Blood Transplant. Recipients

Fetal Maternal Immunity and Antileukemia Activity in Cord Blood Transplant. Recipients Fetal Maternal Immunity and Antileukemia Activity in Cord Blood Transplant Recipients Filippo Milano, 1 J. Lee Nelson, 1, 2 Colleen Delaney 1,3 1 Clinical Research Division, Fred Hutchinson Cancer Research

More information

Relapsed or Refractory Adult Acute Lymphoblastic Leukemia (ALL): Distinct Patient Populations With Significant Unmet Medical Need

Relapsed or Refractory Adult Acute Lymphoblastic Leukemia (ALL): Distinct Patient Populations With Significant Unmet Medical Need Relapsed or Refractory Adult Acute Lymphoblastic Leukemia (ALL): Distinct Patient Populations With Significant Unmet Medical Need Hagop M. Kantarjian, MD Chairman, Leukemia Department Department of Hematology

More information

Second Cancers in Adults

Second Cancers in Adults Second Cancers in Adults This document focuses on second cancers in adults. For information about second cancers after treatment of childhood cancers, see our document Children Diagnosed With Cancer: Late

More information

DESCRIPTION/BACKGROUND

DESCRIPTION/BACKGROUND Original Issue Date (Created): August 23, 2004 Most Recent Review Date (Revised): Effective Date: October 21, 2008 July 1, 2009- RETIRED I. DESCRIPTION/BACKGROUND Hematopoietic Stem-Cell Transplantation

More information

Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014

Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014 ABOUT BLOOD CANCERS Leukemia, Hodgkin lymphoma (HL), non-hodgkin lymphoma (NHL), myeloma, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) are types of cancer that can affect the

More information

EBMT Sunday 30th March 2014

EBMT Sunday 30th March 2014 EBMT Sunday 30th March 2014 Satellite Symposium: ATIR as immunotherapy following haploidentical HSCT: No need for prophylactic immunosuppressants due to low risk of GvHD Chair: Dr. Armand Keating (Toronto,

More information

Acute myeloid leukemia (AML)

Acute myeloid leukemia (AML) Acute myeloid leukemia (AML) Adult acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells, or platelets. Adult

More information

BIOSTATISTICS FOR TRANSLATIONAL & CLINICAL RESEARCH. Blood-&-Marrow Transplants & CANCERS

BIOSTATISTICS FOR TRANSLATIONAL & CLINICAL RESEARCH. Blood-&-Marrow Transplants & CANCERS BIOSTATISTICS FOR TRANSLATIONAL & CLINICAL RESEARCH Blood-&-Marrow Transplants & CANCERS Stem Cells Stem cells are immature body cells that act like "starter dough" because they can make identical copies

More information

Blood and Marrow Stem Cell Transplantation

Blood and Marrow Stem Cell Transplantation Blood and Marrow Stem Cell Transplantation Revised 2013 A Message from Louis J. DeGennaro, PhD President and CEO of The Leukemia & Lymphoma Society The Leukemia & Lymphoma Society (LLS) is committed to

More information

Pr Eliane Gluckman, MD, FRCP, Disclosure of Interest: Nothing to Disclose

Pr Eliane Gluckman, MD, FRCP, Disclosure of Interest: Nothing to Disclose Pr Eliane Gluckman, MD, FRCP, Hospital Saint Louis, University Paris- Diderot, France Should Haplo-identical transplantation be preferred to cord blood in patients without a matched donor? Disclosure of

More information

Stammzelltransplantation. Neues vom immunologischen Ctrl-Alt-Del

Stammzelltransplantation. Neues vom immunologischen Ctrl-Alt-Del Allogene Neues vom immunologischen Ctrl-Alt-Del Prof. Dr. med. Wolfgang Bethge Allogene am ASH Insgesamt 715 Abstracts zum Thema Auswahl: Azacitidine als Überbrückung zu allogenen SZT bei MDS Ergebnis

More information

4. All cord blood banks should be subject to the same standards, regulations and accreditation requirements.

4. All cord blood banks should be subject to the same standards, regulations and accreditation requirements. WMDA Policy Statement on the Utility of Autologous or Family Cord Blood Unit Storage The WMDA Board adopted this policy on 25 th of May 2006. Policy updated _April 2011 The Cord Blood Working Group and

More information

Hematopoietic Stem Cell Transplantation: Evolving Strategies That Have Resulted in Improved Outcomes

Hematopoietic Stem Cell Transplantation: Evolving Strategies That Have Resulted in Improved Outcomes Hematopoietic Stem Cell Transplantation: Evolving Strategies That Have Resulted in Improved Outcomes Asad Bashey, MD, PhD Blood and Marrow Transplantation Program at Northside Hospital Atlanta, Georgia

More information

EUROCORD. in 49 countries and 484 transplant centres* 264 EBMT 4847 (73%) cases 220 Non-EBMT 1797 (27%) cases

EUROCORD. in 49 countries and 484 transplant centres* 264 EBMT 4847 (73%) cases 220 Non-EBMT 1797 (27%) cases ! 21%! EUROCORD 6756 cord blood transplantations performed from 1988 to March 2010 in 49 countries and 484 transplant centres* 264 EBMT 4847 (73%) cases 220 Non-EBMT 1797 (27%) cases * missing center

More information

treatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can

treatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can Shristi Pandey Genomics and Medicine Winter 2011 Prof. Doug Brutlag Chronic Myeloid Leukemia: A look into how genomics is changing the way we treat Cancer. Until the late 1990s, nearly all treatment methods

More information

Protocol. Hematopoietic Stem Cell Transplantation for Breast Cancer

Protocol. Hematopoietic Stem Cell Transplantation for Breast Cancer Protocol Hematopoietic Stem Cell Transplantation for Breast Cancer (80127) Medical Benefit Effective Date: 04/01/13 Next Review Date: 03/17 Preauthorization Yes Review Dates: 04/07, 05/08, 05/09, 03/10,

More information

Disclosures. I have no disclosures.

Disclosures. I have no disclosures. Not Your Own Marrow Jenni Krajewski, MD Clinical Assistant Professor, Rutgers New Jersey Medical School Attending Physician, Pediatric Blood and Marrow Transplantation The Institute for Pediatric Cancer

More information

INFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002

INFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002 INFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002 COVERAGE: SPECIAL COMMENT ON POLICY REVIEW: Due to the complexity of the Peripheral and Bone Marrow Stem Cell Transplantation

More information

Selecting Appropriate Blood Products for Recipients of ABO/Rh Mismatched Stem Cell Transplants. Summary of Significant Changes. Purpose.

Selecting Appropriate Blood Products for Recipients of ABO/Rh Mismatched Stem Cell Transplants. Summary of Significant Changes. Purpose. This Specification replaces SPN/DDR/RC/023/05 (SPN215/1) Copy Number Summary of Significant Changes Change to new document reference numbers. Effective 18/10/11 Removal of ABO titres from sections 3.1

More information

Northside Hospital Blood & Marrow Transplant Program

Northside Hospital Blood & Marrow Transplant Program Northside Hospital Blood & Marrow Transplant Program The Blood & Marrow Transplant roup O F G E O R G I A F O C U S O N T H E PAT I E N T S C O M PA S S I O N AT E C A R E S TAT E - O F - T H E - A R T

More information

Cord Blood: Research Progress and Future Promise

Cord Blood: Research Progress and Future Promise Cord Blood: Research Progress and Future Promise By Al Staropoli, AABB Contributing Writer Sue Fister found out she had leukemia when she was 50 years old. Doctors suggested a bone marrow transplant as

More information

Not All Stem Cells are the Same

Not All Stem Cells are the Same Cord Blood Banking and Transplantation Jennifer Willert, M.D. Hematology/Oncology Blood and Marrow Transplant Rady Children s Hospital San Diego Clinical Professor UCSD Not All Stem Cells are the Same

More information

Cord Cor Blood Banking Scott N. Furlan, MD Ellen S. Plummer, Plummer MD

Cord Cor Blood Banking Scott N. Furlan, MD Ellen S. Plummer, Plummer MD Cord Blood Banking Scott N. Furlan, MD Ellen S.Plummer, MD Overview Background Biology of Stem Cell Transplant Opportunities i at Parkland Logistics of Banking Potential Barriers Indications for HCT Cancer

More information

Blood and Marrow Stem Cell Transplantation LEUKEMIA LYMPHOMA MYELOMA

Blood and Marrow Stem Cell Transplantation LEUKEMIA LYMPHOMA MYELOMA Blood and Marrow Stem Cell Transplantation LEUKEMIA LYMPHOMA MYELOMA Table of Contents Introduction 1 Here to Help 2 Normal Blood and Marrow 4 Overview and Types of Stem Cell Transplantation 6 Stem Cell

More information

Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease

Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease 1 Produced by St. Jude Children s Research Hospital Departments of Hematology, Patient

More information

THE NEW ZEALAND MEDICAL JOURNAL

THE NEW ZEALAND MEDICAL JOURNAL THE NEW ZEALAND MEDICAL JOURNAL Vol 118 No 1208 ISSN 1175 8716 Private umbilical cord blood banking: a biological insurance of dubious future benefit! Michael Sullivan, Peter Browett, Nigel Patton In its

More information

5. All cord blood banks should be subject to the same standards, regulations and accreditation requirements.

5. All cord blood banks should be subject to the same standards, regulations and accreditation requirements. WMDA Policy Statement for the Utility of Autologous or Family Cord Blood Unit Storage (This policy statement has been approved and adopted by the WMDA board on the 25 th of May 2006) The Cord Blood Registries

More information

The immune system. Bone marrow. Thymus. Spleen. Bone marrow. NK cell. B-cell. T-cell. Basophil Neutrophil. Eosinophil. Myeloid progenitor

The immune system. Bone marrow. Thymus. Spleen. Bone marrow. NK cell. B-cell. T-cell. Basophil Neutrophil. Eosinophil. Myeloid progenitor The immune system Basophil Neutrophil Bone marrow Eosinophil Myeloid progenitor Dendritic cell Pluripotent Stem cell Lymphoid progenitor Platelets Bone marrow Thymus NK cell T-cell B-cell Spleen Cancer

More information

Die Periphere Blutstammzell- Transplantation

Die Periphere Blutstammzell- Transplantation Die Periphere Blutstammzell- Transplantation Martin Körbling DGHO, Stuttgart, Oktober 2012 Der Ursprung des Begriffs Stammzelle Alexander Maximow 1909 A. Maximow, Fol. Haematol. 8;1909:125-134 St. Petersburg

More information

Update in Hematology Oncology Targeted Therapies. Mark Holguin

Update in Hematology Oncology Targeted Therapies. Mark Holguin Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning

More information

PT CordLife Indonesia Premium Cordblood Bank. PT CordLife Indonesia Premium Cordblood Bank

PT CordLife Indonesia Premium Cordblood Bank. PT CordLife Indonesia Premium Cordblood Bank Cordblood Stem Cells and The Role of Cordblood Bank in Supporting Stem Cells Research Presentation Overview Company profile Haematopoietic stem cells in cordblood What we can do to help 1 2 PT CordLife

More information

Outcome of Unrelated HSCT in Patients Lacking HLA Matched Related Donors: Iranian Stem Cell Donor Program (ISCDP)

Outcome of Unrelated HSCT in Patients Lacking HLA Matched Related Donors: Iranian Stem Cell Donor Program (ISCDP) Outcome of Unrelated HSCT in Patients Lacking HLA Matched Related Donors: Iranian Stem Cell Donor Program (ISCDP) October 18, 2014 19th Congress of APBMT, Hangzhou, China AMIR ALI HAMIDIEH, MD Iranian

More information

Allogeneic stem cell transplant in HIV-1-infected individuals

Allogeneic stem cell transplant in HIV-1-infected individuals Allogeneic stem cell transplant in HIV-1-infected individuals Javier Martinez-Picado UNIVERSITAT DE VIC Barriers to cure HIV infection Residual Replication Immune activation Inflammation Latent Infection

More information

Leukemias and Lymphomas: A primer

Leukemias and Lymphomas: A primer Leukemias and Lymphomas: A primer Normal blood contains circulating white blood cells, red blood cells and platelets 700 red cells (oxygen) 1 white cell Neutrophils (60%) bacterial infection Lymphocytes

More information

Haematopoietic Chimerism Analysis after Allogeneic Stem Cell Transplantation

Haematopoietic Chimerism Analysis after Allogeneic Stem Cell Transplantation Haematopoietic Chimerism Analysis after Allogeneic Stem Cell Transplantation Dr Ros Ganderton, Ms Kate Parratt, Dr Debbie Richardson, Dr Kim Orchard and Dr Liz Hodges Departments of Molecular Pathology

More information

Corporate Medical Policy Cord Blood as a Source of Stem Cells

Corporate Medical Policy Cord Blood as a Source of Stem Cells Corporate Medical Policy Cord Blood as a Source of Stem Cells File Name: Origination: Last CAP Review: Next CAP Review: Last Review cord_blood_as_a_source_of_stem_cells 2/2001 3/2015 3/2016 3/2015 Description

More information

Objectives. Cord Blood. Case 1. Case 1. Case 1. Case 1. To provide a framework for answering a family s questions about cord blood storage.

Objectives. Cord Blood. Case 1. Case 1. Case 1. Case 1. To provide a framework for answering a family s questions about cord blood storage. Cord Blood Should we save the baby s cord blood? Meghan A. Higman, MD, PhD Clinical Assistant Professor of Pediatrics Division of Pediatric Hematology/Oncology Assistant Professor of Oncology Pediatrics

More information

Maria Teresa Lupo Stanghellini, MD San Raffaele Scientific Institute. Milano, Italy. m.lupostanghellini@hsr.it

Maria Teresa Lupo Stanghellini, MD San Raffaele Scientific Institute. Milano, Italy. m.lupostanghellini@hsr.it : in-vivo HSV-TK suicide machinery is effective in GvHD control and provide a long-term immune-suppressive treatment-free survival Maria Teresa Lupo Stanghellini, MD San Raffaele Scientific Institute.

More information

CHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION

CHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION CHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION Chapter 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION 1.1 OVERVIEW OF THE CORD BLOOD TRANSPLANTATION STUDY Bone marrow transplantation

More information

P R E S S K I T 2013 TABLE OF CONTENTS. About the European Group for Blood and Marrow Transplantation

P R E S S K I T 2013 TABLE OF CONTENTS. About the European Group for Blood and Marrow Transplantation TABLE OF CONTENTS About the European Group for Blood and Marrow Transplantation Haematopoietic Stem Cell Transplantation (HSCT): Key facts & figures EBMT Data - A foundation for cutting-edge research Clinical

More information

Stem Cell Transplantation for Acute Lymphoblastic Leukemia

Stem Cell Transplantation for Acute Lymphoblastic Leukemia Stem Cell Transplantation for Acute Lymphoblastic Leukemia Mona Shafey MD, FRCPC Bone Marrow Transplant Fellow Alberta Blood and Marrow Transplant Program 1 of 14 Stem Cell Transplantation for Acute Lymphoblastic

More information

In a number of genetic, hematologic, and oncologic

In a number of genetic, hematologic, and oncologic AMERICAN ACADEMY OF PEDIATRICS Cord Blood Banking for Potential Future Transplantation: Subject Review ABSTRACT. In recent years, umbilical cord blood, which contains a large number of hematopoietic stem

More information

DEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT

DEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT www.narayanahealth.org DEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT About Narayana Health City Narayana Health, one of India's largest and the world's most economical healthcare service providers

More information

Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood

Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood [Track 2: What Is a Transplant?] Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood can be an effective treatment for people with blood cancers such as leukemia,

More information

On April 4, a group of physicians at the 37th annual

On April 4, a group of physicians at the 37th annual By Ronale Tucker Rhodes, MS Better gene sampling and newer transplant regimens are making stem cell transplantation possible for a host of disease states that previously were rarely considered for this

More information

CML. cure. A Patient s Guide. Molecular Biology Diagnosis Stem Cell Transplant Monitoring New Drugs Questions to Ask and More

CML. cure. A Patient s Guide. Molecular Biology Diagnosis Stem Cell Transplant Monitoring New Drugs Questions to Ask and More A Patient s Guide to CML Molecular Biology Diagnosis Stem Cell Transplant Monitoring New Drugs Questions to Ask and More cure C a n c e r U p d at e s, R e s e a r c h & E d u c at i o n Based on science,

More information

Stem Cell Transplantation In Patients with Fanconi Anemia

Stem Cell Transplantation In Patients with Fanconi Anemia Stem Cell Transplantation In Patients with Fanconi Anemia FARF Annual Family Meeting 6/28/15 Casco, ME Parinda A. Mehta, M.D. Cincinnati Children s Hospital Medical Center Improvements in Unrelated Donor

More information

CAR T cell therapy for lymphomas

CAR T cell therapy for lymphomas CAR T cell therapy for lymphomas Sattva S. Neelapu, MD Associate Professor and Deputy Chair ad interim Department of Lymphoma and Myeloma UT MD Anderson Cancer Center, Houston, TX CAR T cell therapy What

More information

Section: Transplant Last Reviewed Date: January 2015. Policy No: 45.16 Effective Date: April 1, 2015

Section: Transplant Last Reviewed Date: January 2015. Policy No: 45.16 Effective Date: April 1, 2015 Medical Policy Manual Topic: Placental and Umbilical Cord Blood as a Source of Stem Cells Date of Origin: December 2009 Section: Transplant Last Reviewed Date: January 2015 Policy No: 45.16 Effective Date:

More information

The future of unrelated Stem Cell Transplant in the UK: DOH Working Party Findings. Prof. Tony Pagliuca

The future of unrelated Stem Cell Transplant in the UK: DOH Working Party Findings. Prof. Tony Pagliuca The future of unrelated Stem Cell Transplant in the UK: DOH Working Party Findings Prof. Tony Pagliuca UK STEM CELL STRATEGIC FORUM The future of unrelated donor SCT in the UK Antonio Pagliuca, Transplant

More information

Treatment of low-grade non-hodgkin lymphoma

Treatment of low-grade non-hodgkin lymphoma Produced 28.02.2011 Due for revision 28.02.2013 Treatment of low-grade non-hodgkin lymphoma Lymphomas are described as low grade if the cells appear to be dividing slowly. There are several kinds of low-grade

More information

Blood and Marrow Stem Cell Transplantation

Blood and Marrow Stem Cell Transplantation Blood and Marrow Stem Cell Transplantation Printing of this publication made possible by an education grant from Table of Contents Introduction 2 Overview of Stem Cell Transplantation 3 Normal Blood and

More information

A Cure for Sickle Cell Anemia and Thalassemia

A Cure for Sickle Cell Anemia and Thalassemia IV Simpósio Internacional de Hemoglobinopatias A Cure for Sickle Cell Anemia and Thalassemia Bertram Lubin, MD and Mark Walters, MD 4 September 2007 Topics to be covered Cord blood: Importance and biology

More information

Hematopoietic Stem-Cell Transplantation for Epithelial Ovarian Cancer

Hematopoietic Stem-Cell Transplantation for Epithelial Ovarian Cancer Hematopoietic Stem-Cell Transplantation for Epithelial Ovarian Cancer Policy Number: Original Effective Date: MM.07.014 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 01/23/2015 Section:

More information

My Sister s s Keeper. Science Background Talk

My Sister s s Keeper. Science Background Talk My Sister s s Keeper Science Background Talk Outline Acute promyelocytic leukemia (APL) APL Treatment Savior Siblings In vitro fertilization (IVF) Pre-implantation Genetic Diagnosis (PGD) Risks of donating

More information

UMBILICAL-CORD BLOOD TRANSPLANTATION FOR THE TREATMENT OF CANCER

UMBILICAL-CORD BLOOD TRANSPLANTATION FOR THE TREATMENT OF CANCER UMBILICAL-CORD BLOOD TRANSPLANTATION FOR THE TREATMENT OF CANCER Juliet N. Barker* and John E. Wagner Haematopoietic stem-cell transplantation is used to treat many haematological cancers, but is limited

More information

2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders

2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders UPDATE ECIL-4 2011 2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders Jan Styczynski, Hermann Einsele, Rafael de la Camara, Catherine Cordonnier,

More information

Immunoablative therapy with autologous hematopoietic stem cell transplantation in the treatment of poor risk multiple sclerosis

Immunoablative therapy with autologous hematopoietic stem cell transplantation in the treatment of poor risk multiple sclerosis Immunoablative therapy with autologous hematopoietic stem cell transplantation in the treatment of poor risk multiple sclerosis T Kozák, P Lhotáková Department of Clinical Haematology, 3r d School of Medicine,

More information

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials OUR FOCUS ABOUT emerging treatments Presentation for: Judith E. Karp, MD Advancements for Acute Myelogenous Leukemia Supported by an unrestricted educational

More information

DECISION AND SUMMARY OF RATIONALE

DECISION AND SUMMARY OF RATIONALE DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Clofarabine in the treatment of relapsed acute myeloid leukaemia (AML) The application was for clofarabine to remain in

More information

The Treatment of Leukemia

The Treatment of Leukemia The Treatment of Leukemia Guest Expert: Peter, MD Associate Professor of Hematology Director, Yale Cancer Center Leukemia Program www.wnpr.org www.yalecancercenter.org Hi, I am Bruce Barber and welcome

More information

UMBILICAL CORD BLOOD HARVESTING & STORAGE

UMBILICAL CORD BLOOD HARVESTING & STORAGE Protocol: TRP009 Effective Date: October 14, 2013 UMBILICAL CORD BLOOD HARVESTING & STORAGE Table of Contents Page COMMERCIAL, MEDICARE & MEDICAID COVERAGE RATIONALE... 1 BACKGROUND... 2 CLINICAL EVIDENCE...

More information

Developments and Quality Assurance in Stem Cell Transplantation

Developments and Quality Assurance in Stem Cell Transplantation This text is a translation from the original German which should be used for referencing. The German version is authoritative. ORIGINAL ARTICLE Developments and Quality Assurance in Stem Cell Transplantation

More information

What we will discuss today

What we will discuss today Umbilical cord blood banking It s Utility? Dr. Nita Radhakrishnan Pediatric Hematology Oncology Unit, Sir Ganga Ram Hospital, New Delhi What we will discuss today What are stem cells? What are the sources

More information

Cord blood Banking Transplant List for One USA Bank - StemCyte www.stemcyte.com/cordblood-banking-transplant-list

Cord blood Banking Transplant List for One USA Bank - StemCyte www.stemcyte.com/cordblood-banking-transplant-list Cells4Life is the oldest and largest cord blood storage company in the UK. We are governed by some of the world's most stringent medical laws, and are currently the only stem cell storage company in the

More information

Umbilical Cord Blood Banking: Implications for Perinatal Care Providers

Umbilical Cord Blood Banking: Implications for Perinatal Care Providers SOGC CLINICAL PRACTICE GUIDELINES No 156, March 2005 Umbilical Cord Blood Banking: Implications for Perinatal Care Providers This guideline has been reviewed by the Maternal/Fetal Medicine Committee and

More information

Acute Lymphoblastic Leukemia (Adult) Including Lymphoblastic lymphoma

Acute Lymphoblastic Leukemia (Adult) Including Lymphoblastic lymphoma Acute Lymphoblastic Leukemia (Adult) Including Lymphoblastic lymphoma Updated April 2008 by Dr. Richard Wells* Updates: Minor changes only Introduction Acute lymphocytic leukemia (ALL) is a relatively

More information

TRANSPLANT BASICS Understanding transplant and how it works

TRANSPLANT BASICS Understanding transplant and how it works TRANSPLANT BASICS Understanding transplant and how it works Thuy, transplant recipient AT EVERY STEP, WE ARE HERE TO HELP As you journey through transplant, you re not alone. Be The Match is ready to help.

More information

PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA PROGNOSIS IN ACUTE MYELOID LEUKEMIA

PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA PROGNOSIS IN ACUTE MYELOID LEUKEMIA PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA UNFAVORABLE Advanced age High leukocyte count at diagnosis Presence of myeloid antigens Late achievement of CR Chromosomal abnormalities: t(9:22)(q34:q11) t(4;11)(q21;q23)

More information

NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript NIH Public Access Author Manuscript Published in final edited form as: Bone Marrow Transplant. 2010 May ; 45(5): 807 810. doi:10.1038/bmt.2010.10. The World Marrow Donor Association: Twenty Years of International

More information

Stem Cell Banking. Umbilical Cord. The Leading Cell Bank www.stemology.co.uk. Protect your family s future

Stem Cell Banking. Umbilical Cord. The Leading Cell Bank www.stemology.co.uk. Protect your family s future Protect your family s future The Leading Cell Bank www.stemology.co.uk Stem Cell Banking Umbilical Cord For women in their 1st, 2nd or 3rd Trimester of Pregnancy Introduction to Stemology Imagine you

More information

Your Cord Blood Donation Options

Your Cord Blood Donation Options Your Cord Blood Donation Options Our Mission To develop and maintain a statewide resource for potentially life-saving cord blood to treat children and adults. What is cord blood? Cord blood is the blood

More information

Corporate Medical Policy Cord Blood as a Source of Stem Cells

Corporate Medical Policy Cord Blood as a Source of Stem Cells Corporate Medical Policy Cord Blood as a Source of Stem Cells File Name: Origination: Last CAP Review: Next CAP Review: Last Review cord_blood_as_a_source_of_stem_cells 2/2001 3/2015 3/2016 3/2015 Description

More information

Sibling Donor Cord Blood Transplantation for Thalassemia Major: Experience of the Sibling Donor Cord Blood Program

Sibling Donor Cord Blood Transplantation for Thalassemia Major: Experience of the Sibling Donor Cord Blood Program Sibling Donor Cord Blood Transplantation for Thalassemia Major: Experience of the Sibling Donor Cord Blood Program MARK C. WALTERS, LYNN QUIROLO, ELIZABETH T. TRACHTENBERG, SANDIE EDWARDS, LISA HALE, JOANNA

More information